5-(2-吡啶基)-1,3-噁唑 | 70380-73-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 5-(2-吡啶基)-1,3-噁唑
• 中文别名: 5-(2-吡啶基)-1,3-恶唑
• 英文名称: 5-(pyridin-2-yl)oxazole
• 英文别名: 5-(2-pyridyl)oxazole；2-oxazol-5-ylpyridine；5-(2-pyridyl)-1,3-oxazole；5-pyridin-2-yl-1,3-oxazole
• CAS: 70380-73-3
• 化学式: C₈H₆N₂O
• mdl: MFCD00085160
• 分子量: 146.148
• InChiKey: LUMKXMDGONYZHO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  38.9
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 危险品标志：
  Xi
• 海关编码：
  2934999090

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
5-(2-Pyridyl)-1,3-oxazole
Product Name:
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.
H315: Causes skin irritation
H319: Causes serious eye irritation
H335: May cause respiratory irritation
P261: Avoid breathing dust/fume/gas/mist/vapours/spray
Wear protective gloves/protective clothing/eye protection/face protection
P280:
P305+P351+P338: IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present
and easy to do – continue rinsing
P304+P340: IF INHALED: Remove victim to fresh air and keep at rest in a position comfortable for breathing
P405: Store locked up

---

Section 3. Composition/information on ingredients.
5-(2-Pyridyl)-1,3-oxazole
Ingredient name:
CAS number: 70380-73-3

---

Section 4. First aid measures
Immediately wash skin with copious amounts of water for at least 15 minutes while removing
Skin contact:
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.
Ingestion:

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels, refrigerated.

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Not specified
Appearance:
Boiling point: No data
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C8H6N2O
Molecular weight: 146.1

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  5-(2-吡啶基)-1,3-噁唑 在 bis-triphenylphosphine-palladium(II) chloride 、 四丁基氟化铵 作用下， 以 四氢呋喃 为溶剂， 反应 28.66h， 生成 1-oxo-1-[5-(2-pyridyl)oxazol-2-yl]-7-(4-nitrophenyl)hept-6-yne
  参考文献：
  名称：

  Structure−Activity Relationships of α-Ketooxazole Inhibitors of Fatty Acid Amide Hydrolase

  摘要：

  A systematic study of the structure-activity relationships of 2b (OL-135), a potent inhibitor of fatty acid amide hydrolase (FAAH), is detailed targeting the C2 acyl side chain. A series of aryl replacements or substituents for the terminal phenyl group provided effective inhibitors (e.g., 5c, aryl = 1- napthyl, K-i = 2.6 nM), with 5hh (aryl = 3-ClPh, K-i = 900 pM) being 5-fold more potent than 2b. Conformationally restricted C2 side chains were examined, and many provided exceptionally potent inhibitors, of which 11j (ethylbiphenyl side chain) was established to be a 750 pM inhibitor. A systematic series of heteroatoms (O, NMe, S), electron-withdrawing groups (SO, SO2), and amides positioned within and hydroxyl substitutions on the linking side chain were investigated, which typically led to a loss in potency. The most tolerant positions provided effective inhibitors (12p, 6-position S, K-i = 3 nM, or 13d, 2-position OH, K-i = 8 nM) comparable in potency to 2b. Proteome-wide screening of selected inhibitors from the systematic series of > 100 candidates prepared revealed that they are selective for FAAH over all other mammalian serine proteases.

  DOI：

  10.1021/jm061414r
• 作为产物：
  描述：

  恶唑 、 2-氯吡啶 在 palladium diacetate 、 potassium carbonate 、 正丁基二(1-金刚烷基)膦 、 三甲基乙酸 作用下， 以 2,4-滴二甲胺盐 为溶剂， 反应 16.0h， 以58%的产率得到5-(2-吡啶基)-1,3-噁唑
  参考文献：
  名称：

  高区域选择性钯催化的芳基溴化物，氯化物和三氟甲磺酸酯在C-2或C-5处恶唑的直接芳基化

  摘要：

  已经开发了在钯C-5和C-2上具有高区域选择性（> 100：1）的芳基直接芳基化的互补钯催化方法，适用于各种芳基和杂芳基溴化物，氯化物，碘化物和三氟甲磺酸酯。在带有膦5或6的极性溶剂中，C-5芳基化是优选的，而在非极性溶剂和膦3中，C-2芳基化是优选的。生物活性分子的合成。此外，在机械观测的基础上，提出了这两个相互竞争的芳基化过程的潜在机制。

  DOI：

  10.1021/ol1011778
• 作为试剂：
  描述：

  4-氟苯硼酸 、 ((1S,2S,3R)-2-butyl-3-((E)-2-methylpent-1-en-1-yl)-2-methylcyclopropyl)methanol 在 对甲苯磺酸双（乙腈）钯（II） 、 氧气 、 copper(II) bis(trifluoromethanesulfonate) 、 5-(2-吡啶基)-1,3-噁唑 作用下， 以 N,N-二甲基乙酰胺 为溶剂， 55.0 ℃ 、101.33 kPa 条件下， 反应 18.0h， 以71%的产率得到
  参考文献：
  名称：

  具有连续立体元素的不饱和无环片段的高效和立体发散合成

  摘要：

  能够催化和快速组装在无环系统中具有多个立体中心的大量有机化合物的合成有机策略有些罕见，尤其是在达到当今的高效率和选择性标准时。特别是，催化制备具有多个立体中心的简单无环烃骨架的三维分子布局仍然是一个非常未知的领域。在这里，我们报告了一种快速、模块化、立体发散和面向多样性的统一策略来构建无环分子框架，该框架承载多达四个连续和拥挤的立体元素，具有非常高水平的立体控制，并且只需三个催化步骤即可从市售的炔烃中获得。

  DOI：

  10.1038/s41557-018-0123-7

文献信息

• Gamma-hydroxy-2-(fluoroalkylaminocarbonyl)-1-piperazinepentanamides and uses thereof
  申请人：Merck & Co., Inc.

  公开号：US06642237B1

  公开（公告）日：2003-11-04

  &ggr;-Hydroxy-2-(fluoroalkylaminocarbonyl)-1-piperazinepentanamide compounds are inhibitors of HIV protease and inhibitors of HIV replication. These compounds are useful in the prevention or treatment of infection by HV and the treatment of AIDS, either as compounds, pharmaceutically acceptable salts, pharmaceutical composition ingredients, whether or not in combination with other antivirals, immunomodulators, antibiotics or vaccines. Methods of treating AIDS and methods of preventing or treating infection by HIV are also described. These compounds are effective against HIV viral mutants which are resistant to HIV protease inhibitors currently used for treating AIDS and HIV infection.

  -Hydroxy-2-(氟烷基氨基甲酰)-1-哌嗪戊二酰胺化合物是HIV蛋白酶的抑制剂，也是HIV复制的抑制剂。这些化合物在预防或治疗HV感染以及治疗艾滋病方面非常有用，无论是作为化合物、药学上可接受的盐、药物组成成分，还是与其他抗病毒药物、免疫调节剂、抗生素或疫苗组合使用。还描述了治疗艾滋病的方法以及预防或治疗HIV感染的方法。这些化合物对目前用于治疗艾滋病和HIV感染的HIV蛋白酶抑制剂产生耐药性的HIV病毒突变体具有有效作用。
• 1,3-BENZOTHIAZINONE DERIVATIVES AND USE THEREOF
  申请人：Takeda Chemical Industries, Ltd.

  公开号：EP1424336A1

  公开（公告）日：2004-06-02

  This invention provides a compound represented by the formula (I) : wherein R1 is a hydrogen atom, a halogen atom, hydroxy, nitro, optionally halogenated alkyl, alkoxy optionally having substituents, acyl or amino optionally having substituents; R2 is pyridyl, furyl, thienyl, pyrrolyl, quinolyl, pyrazinyl, pyrimidinyl, pyridazinyl, indolyl, tetrahydroquinolyl or thiazolyl, each of which may have substituents; n is 1 or 2; or a salt. And this invention provides a safe pharmaceutical comprising the compound of the formula (I) , which has an excellent apoptosis inhibitory effect and MIF binding effect, for preventing and/or treating heart disease, nervous degenerative disease, cerebrovascular disease, central nervous infectious disease, traumatorathy, demyelinating disease, bone and articular disease, kidney disease, liver disease, osteomyelodysplasia, AIDS, cancer, and the like.

  这项发明提供了一种由以下式（I）表示的化合物： 其中R1是氢原子、卤素原子、羟基、硝基、可选择具有卤素取代基的烷基、可选择具有取代基的烷氧基、酰基或氨基； R2是吡啶基、呋喃基、噻吩基、吡咯基、喹啉基、吡嗪基、嘧啶基、吡啶并嘧啶基、吲哚基、四氢喹啉基或噻唑基，每种基团可能具有取代基； n为1或2；或其盐。该发明提供了一种安全的药物，包括具有优异的凋亡抑制作用和MIF结合作用的式（I）化合物，用于预防和/或治疗心脏病、神经退行性疾病、脑血管疾病、中枢神经感染性疾病、创伤病变、脱髓鞘疾病、骨骼和关节疾病、肾脏疾病、肝脏疾病、骨髓发育不良、艾滋病、癌症等。
• Reactions between Weinreb Amides and 2-Magnesiated Oxazoles:  A Simple and Efficient Preparation of 2-Acyl Oxazoles
  作者：Daniel J. Pippel、Christopher M. Mapes、Neelakandha S. Mani

  DOI：10.1021/jo070646a

  日期：2007.7.1

  Treatment of oxazole or 5-aryl oxazoles with i-PrMgCl smoothly generates the corresponding 2-Grignard reagents, which react with Weinreb amides to provide exclusively 2-acyl oxazole products.

  用i - PrMgCl处理恶唑或5-芳基恶唑会平稳生成相应的2-格利雅试剂，这些试剂会与Weinreb酰胺反应，仅生成2-酰基恶唑产品。
• Discovery of a Potent, Selective, and Efficacious Class of Reversible α-Ketoheterocycle Inhibitors of Fatty Acid Amide Hydrolase Effective as Analgesics
  作者：Dale L. Boger、Hiroshi Miyauchi、Wu Du、Christophe Hardouin、Robert A. Fecik、Heng Cheng、Inkyu Hwang、Michael P. Hedrick、Donmienne Leung、Orlando Acevedo、Cristiano R. W. Guimarães、William L. Jorgensen、Benjamin F. Cravatt

  DOI：10.1021/jm049614v

  日期：2005.3.1

  Herein we report the discovery of a potent, selective, and efficacious class of reversible FAAH inhibitors that produce analgesia in animal models validating a new therapeutic target for pain intervention. Key to the useful inhibitor discovery was the routine implementation of a proteomics-wide selectivity screen against the serine hydrolase superfamily ensuring selectivity for FAAH coupled with systematic

  脂肪酸酰胺水解酶 (FAAH) 在其作用部位降解神经调节脂肪酸酰胺，包括 anandamide（内源性大麻素激动剂）和油酰胺（睡眠诱导脂质），并密切参与其调节。在这里，我们报告了在动物模型中发现了一种有效的、选择性的和有效的可逆 FAAH 抑制剂，它们可以产生镇痛作用，从而验证了疼痛干预的新治疗靶点。发现有用抑制剂的关键是常规实施针对丝氨酸水解酶超家族的蛋白质组学选择性筛选，确保对 FAAH 的选择性，并结合候选抑制剂的系统体内检查。
• Pd-Catalyzed Desulfonative Cross-Coupling of Benzylic Sulfone Derivatives with 1,3-Oxazoles
  作者：Jacky C.-H. Yim、Masakazu Nambo、Cathleen M. Crudden

  DOI：10.1021/acs.orglett.7b01510

  日期：2017.7.21

  The Pd-catalyzed desulfonative cross-coupling reaction of benzylic sulfone derivatives with 1,3-oxazoles via a deprotonative pathway has been developed. Broad substrate scope for both sulfone and 1,3-oxazole partners is observed, affording a variety of 1,3-oxazole-containing triarylmethanes. Sulfone partners that are primary benzylic, secondary benzylic, and benzhydryl are all effective. Using this

  已经开发了通过去质子途径的苄基砜衍生物与1,3-恶唑的Pd催化脱硫交叉偶联反应。观察到砜和1，3-恶唑伴侣的底物范围宽，提供了多种含1，3-恶唑的三芳基甲烷。伯苄基，仲苄基和二苯甲基的砜伴侣均有效。使用这种方法，已经证明了多元芳构结构的直接合成。